Charles Schwab Investment Management Inc. Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Charles Schwab Investment Management Inc. increased its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 3.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 93,517 shares of the company’s stock after acquiring an additional 3,024 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in UroGen Pharma were worth $996,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after purchasing an additional 48,040 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after buying an additional 49,318 shares during the last quarter. Geode Capital Management LLC raised its stake in UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in UroGen Pharma during the 4th quarter worth approximately $126,000. Finally, State Street Corp grew its position in shares of UroGen Pharma by 5.9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after acquiring an additional 42,907 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

Analyst Ratings Changes

URGN has been the subject of several recent research reports. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. HC Wainwright cut their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Stock Down 2.2 %

URGN stock opened at $11.20 on Monday. The stock has a market cap of $516.25 million, a PE ratio of -3.56 and a beta of 1.12. The firm’s 50-day simple moving average is $10.66 and its 200 day simple moving average is $11.49. UroGen Pharma Ltd. has a fifty-two week low of $9.03 and a fifty-two week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. As a group, sell-side analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.